The FDA has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
This study used data from the Nurses’ Health Study (NHS) and NHS2 to explore the association between height, number of nevi, and risk of invasive melanoma.
The dermoscopic features and differential diagnosis in dermoscopic examination of sebaceous carcinoma are analyzed.
Strategies for the management of advanced melanoma during the coronavirus disease 2019 (COVID-19) pandemic are provided.
Black patients are more likely to experience a longer delay from diagnosis to surgery vs white patients with melanoma.
Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot be ruled out based on current evidence.
Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.
The long-term outcome of patients with melanoma may be predicted by FDG-PET imaging and also influence treatment duration.
Findings suggest that PET/CT imaging should be included in the malignant melanoma treatment algorithm starting with T2 patients.
The frequent and durable responses to PD-1/PD-L1–blocking antibodies confirm the importance of immune mechanisms in nonmelanoma skin cancer pathogenesis.